Browse Category

Pharmaceuticals 28 November 2025 - 3 December 2025

Septerna Shares (SEPN) Surge 23% Following Positive SEP-479 Signal, Exceeding Analyst Predictions
Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Stock (PFE) Today – Price, Metsera Obesity Bet, RSV Vaccine Tailwinds and 2026 Forecast (3 December 2025)

Pfizer Inc. remains one of the most closely watched healthcare stocks as of December 3, 2025. The share price is still stuck near post‑COVID lows, but a new $10 billion obesity‑drug acquisition, expanding RSV vaccine markets and a hefty dividend yield around 6.5–7% are reshaping the narrative around the stock. Pfizer+2Pfizer+2
3 December 2025
···
Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals (REGN) Stock Outlook: Morgan Stanley Downgrade, Eylea HD Win and Gene‑Editing Push – December 3, 2025Regeneron

Regeneron Pharmaceuticals, Inc. is ending 2025 in full “complex biotech” mode: the share price has rebounded, the dividend is now real, a flagship drug just got a powerful new label, a rare-disease medicine crushed a Phase 3 trial, and Wall Street is suddenly a bit less euphoric about the stock.
3 December 2025
··
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025

GSK plc heads into the final month of 2025 near multi‑year highs, powered by a strong run of earnings beats, a revived oncology franchise and a looming change at the top of the company. As of 2 December 2025, the stock sits close to its 52‑week peak while analyst opinion remains broadly neutral and focused on whether the pipeline can deliver enough growth to meet GSK’s ambitious 2031 revenue targets. Hargreaves Lansdown+2Yahoo Finance+2
2 December 2025
····
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly and Company has just wrapped up one of the most dramatic months in its history. The drugmaker’s shares have surged in November, pushing the company past a $1 trillion market value and cementing its role as the stock market’s flagship obesity‑drug play. At the same time, fresh commentary this weekend is increasingly focused on one question: is Lilly’s stock now priced for perfection?
30 November 2025
··
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie Inc. heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1
29 November 2025
···
1 … 37 38 39 40 41 … 47
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Taiwan Semiconductor

NYSE: TSM 96 / 100
#2 BUY

AerCap

NYSE: AER 95 / 100
#3 BUY ON PULLBACK

Constellation Energy

NASDAQ: CEG 93 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

American International Group

NYSE: AIG 87 / 100
View full portfolio
Editorial model selection. Not personalised advice.